losartan has been researched along with Muscular Diseases in 8 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Muscular Diseases: Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spontaneous rectus sheath haematomas and cough secondary to losartan are individually rare conditions." | 7.83 | Rare case of losartan-induced cough complicated by rectus sheath haematoma: in a patient on rivaroxaban therapy. ( Ahmed, S; Sweigart, J; Talari, G; Talari, P, 2016) |
| "Losartan is a Food and Drug Administration approved antihypertensive medication that is recently emerging as an antifibrotic therapy." | 5.40 | Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. ( Corona, BT; Garg, K; Walters, TJ, 2014) |
| " Inhibition of TGFβ signaling by Losartan treatment greatly improved the phenotype of myopathies associated with laminin-α2-deficient congenital muscular dystrophy." | 4.88 | TGFβ signaling: its role in fibrosis formation and myopathies. ( Cohn, RD; MacDonald, EM, 2012) |
| "Spontaneous rectus sheath haematomas and cough secondary to losartan are individually rare conditions." | 3.83 | Rare case of losartan-induced cough complicated by rectus sheath haematoma: in a patient on rivaroxaban therapy. ( Ahmed, S; Sweigart, J; Talari, G; Talari, P, 2016) |
| "Losartan is a Food and Drug Administration approved antihypertensive medication that is recently emerging as an antifibrotic therapy." | 1.40 | Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury. ( Corona, BT; Garg, K; Walters, TJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Motherwell, JM | 1 |
| Dolan, CP | 1 |
| Kanovka, SS | 1 |
| Edwards, JB | 1 |
| Franco, SR | 1 |
| Janakiram, NB | 1 |
| Valerio, MS | 1 |
| Goldman, SM | 1 |
| Dearth, CL | 1 |
| Garg, K | 1 |
| Corona, BT | 1 |
| Walters, TJ | 1 |
| Hwang, OK | 1 |
| Park, JK | 2 |
| Lee, EJ | 2 |
| Lee, EM | 2 |
| Kim, AY | 2 |
| Jeong, KS | 2 |
| Talari, G | 1 |
| Talari, P | 1 |
| Sweigart, J | 1 |
| Ahmed, S | 1 |
| Gharaibeh, B | 1 |
| Chun-Lansinger, Y | 1 |
| Hagen, T | 1 |
| Ingham, SJ | 1 |
| Wright, V | 1 |
| Fu, F | 1 |
| Huard, J | 1 |
| Ki, MR | 1 |
| You, SY | 1 |
| Han, SY | 1 |
| Hong, IH | 1 |
| Kwon, SH | 1 |
| Kim, SJ | 1 |
| Rando, TA | 1 |
| MacDonald, EM | 1 |
| Cohn, RD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for losartan and Muscular Diseases
| Article | Year |
|---|---|
Biological approaches to improve skeletal muscle healing after injury and disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Humans; Losartan; Muscle, | 2012 |
TGFβ signaling: its role in fibrosis formation and myopathies.
Topics: Animals; Caveolin 3; Disease Models, Animal; Fibrosis; Humans; Losartan; MicroRNAs; Muscle, Skeletal | 2012 |
6 other studies available for losartan and Muscular Diseases
| Article | Year |
|---|---|
Effects of Adjunct Antifibrotic Treatment within a Regenerative Rehabilitation Paradigm for Volumetric Muscle Loss.
Topics: Animals; Fibrosis; Losartan; Medicine; Motor Activity; Muscle, Skeletal; Muscular Diseases | 2023 |
Losartan administration reduces fibrosis but hinders functional recovery after volumetric muscle loss injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Dose-Response Relationship | 2014 |
Therapeutic Effect of Losartan, an Angiotensin II Type 1 Receptor Antagonist, on CCl₄-Induced Skeletal Muscle Injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Carbon Tetrachloride; Disease Models, | 2016 |
Rare case of losartan-induced cough complicated by rectus sheath haematoma: in a patient on rivaroxaban therapy.
Topics: Aged; Antihypertensive Agents; Cough; Diagnosis, Differential; Factor Xa Inhibitors; Hematoma; Human | 2016 |
Losartan improves adipose tissue-derived stem cell niche by inhibiting transforming growth factor-β and fibrosis in skeletal muscle injury.
Topics: Adipose Tissue; Animals; Coculture Techniques; Fibrosis; Immunoblotting; Losartan; Male; Mice; Mice, | 2012 |
[Myalgia during treatment with Cozaar].
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Humans; Imidazoles; Losartan; Male; Muscular Dise | 1995 |